UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Title of each class | Trading
Symbol(s) |
Name
of each exchange on which registered |
The |
Item 8.01 Other Events.
As previously reported in its Current Report on Form 8-K filed on May 12, 2023, Jaguar Health, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price for the Company’s common stock for the last 30 consecutive business days was below the $1.00 per share minimum required for continued listing under Nasdaq Listing Rule 5550(a)(2). On June 25, 2024, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the minimum bid price deficiency had been cured and that Nasdaq had determined to continue the listing of the Company’s common stock on The Nasdaq Stock Market.
On June 26, 2024, the Company issued a press release with respect to the foregoing, a copy of which is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1 | Press Release, dated June 26, 2024. | |
104 | Cover Page Interactive Data File (embedded with the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JAGUAR HEALTH, INC. | |||
By: | /s/ Lisa A. Conte | ||
Name: | Lisa A. Conte | ||
Title: | Chief Executive Officer & President | ||
Date: June 26, 2024 |
Exhibit 99.1
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
JAGX’s securities continue to be listed and traded on Nasdaq
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
San Francisco, CA (June 26, 2024): Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”) today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that Jaguar has regained compliance with Nasdaq’s minimum bid price requirement.
“We are very happy that Jaguar has regained compliance with Nasdaq. We consider our Nasdaq listing an asset of the Company,” said Lisa Conte, Jaguar’s president and CEO. “A Jaguar investor webcast held on or before July 23, 2024 will provide updates on Jaguar’s advancing cancer supportive care portfolio, and will include members of Jaguar’s scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.”
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer also is the subject of Napo’s phase 3 OnTarget clinical trial for preventive treatment of cancer therapy-related diarrhea (CTD). Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the expectation that Jaguar will report the results of the OnTarget trial on or before July 23, 2024, and the expectation that Jaguar will hold an investor webcast on or before July 23, 2024 regarding updates on the Company's cancer supportive care portfolio. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
M.G/V?(FG)7FX\L:CO[U[NZ2^P_V;_$/C?Q3\#/A9XG^(FH1ZKXR
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MYW*]:;4KM]+L@+:PFFBV10I)/:
M113&*.8K'O" KM'][NE>"?!FA>%K3P-I7A/PYIOA'3+*'1]/\)V6AZ7;:+#
MI]I D%OIMGIL\*Z;/9BR"1@*@*JKK+LE62*+\YOC'_P1Y_85^,\^KZHGPPN/
MAMX@U:1IIM;^%^N:EX1DAGD?S))8]'MII_"]QND!9UET>Z@\QG!0AF%>UG\/
M#KC?%5/$#A./$G^KA@LIGG>)GF.7TG"K"NLRQ& HPP[K9S3J*5##YA.K
M*-# 5*F#C!N?M%^/YAX;Y_AYYAF.2YEAWB,PQ,ZM7#O"U*7LZ$^>?LU4>(FI
M6J
Cover |
Jun. 25, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jun. 25, 2024 |
Entity File Number | 001-36714 |
Entity Registrant Name | JAGUAR HEALTH, INC. |
Entity Central Index Key | 0001585608 |
Entity Tax Identification Number | 46-2956775 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 200 Pine Street |
Entity Address, Address Line Two | Suite 400 |
Entity Address, City or Town | San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94104 |
City Area Code | 415 |
Local Phone Number | 371-8300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, Par Value $0.0001 Per Share |
Trading Symbol | JAGX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
S2R&Q@/1]X?RS07F&' A2=VTN\)YZ4F+I7'WHF
M)>8]%^4]HAU:,FD;.9%'2<6